Markers of Vascular Damage and Repair by Uta Erdbruegger et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
9 
Markers of Vascular Damage and Repair  
Uta Erdbruegger1, Ajay Dhaygude2 and Alexander Woywodt2 
1Division of Nephrology, University of Virginia at Charlottesville, Charlottesville,  
2Renal Unit, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Lancashire, 
1USA 
 2United Kingdom 
1. Introduction 
Damage to endothelial cells is a crucial event during the pathogenesis of vasculitis. The 
vasculitides cause different clinical manifestations, depending on the extent and acuity of 
endothelial damage as well as their preponderance to affect some organ-specific 
endothelial cells and spare others. About 40 years ago circulating endothelial cells (CEC) 
were first observed in peripheral blood. Since then CEC have been established as a 
reliable indicator of vascular injury and damage and more sophisticated detection 
techniques, such as immunomagnetic isolation and fluorescence-activated cell sorting 
(FACS), have become available to detect and enumerate them. Based on current concepts 
of pathogenesis, detached endothelial cells, and/or their soluble and cellular debris, must 
be detectable in peripheral blood of vasculitis patients. In hindsight, it is therefore 
surprising that for many years few, if any, attempts were made to evaluate their use as 
clinically relevant markers of endothelial damage. Endothelial Microparticles (eMP) have 
been described as another potential marker of endothelial damage. eMP are markers of 
activation, cell injury or apoptosis. They are the product of exocytic budding and consist 
of cytoplasmic components and phospholipids. Fluorescence-activated cell sorting (FACS) 
is the preferred technology for isolating MP and different surface markers of the parent 
cells have been used. eMP can reflect endothelial activation and damage, although 
differences between eMP and CEC remain ill-defined. Another approach to measuring 
endothelial damage is to assay soluble markers, such as thrombomodulin or von 
Willebrand factor. However, these markers also have their limitations. It is also 
worthwhile to remember that all approaches struggle with the fact that many endothelial 
markers are also expressed on non-endothelial cells (Table 1). More recently, interest has 
focused on endothelial repair and damage and endothelial progenitor cells have been 
studied, again with different methodologies. Recent evidence has also revealed interesting 
interactions between CEC and healthy endothelium in vitro although the relevance of 
these findings for human vascular disease in vivo remains unclear. Here, we review 
markers of endothelial damage and repair in vasculitis. We discuss the implications of 
these findings for the pathogenesis, their potential clinical utility, and also review the 
limitations of each approach. Finally, we review the phenotype of CEC, mechanisms of 
detachment and interactions with other cell subsets.  
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2. Soluble endothelial markers  
Endothelial cells express a broad variety of proteins 1 but only few of these have been 
studied in serum or plasma in vascular disease. Currently, von Willebrand factor (vWF), 
thrombomodulin 2, soluble E-Selectin and circulating angiopoietin 3 are best described 4-7. It 
must be noted that several factors may influence the levels of these circulating proteins. For 
example, thrombomodulin undergoes renal excretion. Hence, serum levels are influenced by 
renal function. Other confounding factors, such as liver function, clotting or fibrinolysis may 
also influence these proteins. In addition, these soluble markers do not distinguish between 
endothelial activation and damage. Some investigators compared levels of these markers 
with numbers of CECs. A recent study found a correlation between CECs, von Willebrand 
factor (p=0.002) and plasma tissue factor (p=0.02) 8. It is also clear that necrotic endothelial 
cells will release, either in situ or after their detachment from the basement membrane, a 
variety of other, nonspecific, soluble factors. In this regard, Bruchfeld and colleagues 
recently reported elevated levels of High-mobility group box-1 protein (HMGB1), a nuclear 
and cytosolic protein that is released from necrotic cells 9. However HMGB1 is also actively 
secreted from monocytes and macrophages. Angiopoietin-2 (Ang-2) is another new soluble 
marker investigated in small vessel vasculitis. Ang-2 is bound to the endothelial specific 
angiopoietin Tie Ligand–receptor, which is a regulator of endothelial cell detachment. 
Circulating Ang-2 is elevated in small vessel vasculitis and closely correlates with vasculitis 
activity score 3. Ang-2 therefore reflects a potential new mediator of endothelial cell 
detachment in vasculitis although theses findings need to be validated by analyzing a larger 
cohort. 
 
CD/antigen name Other names Expression by non-endothelial cells 
CD31 PECAM-1 Platelets, monocytes, neutrophils, T cell subsets 
CD62e  E-selectin Activated endothelial cells 
CD54 ICAM-1 
Endothelial cells, activated B and T 
lymphocytes, monocytes 
CD105 Endoglin 
Endothelial cells, activated monocytes, tissue 
macrophages, erythroid marrow precursors 
CD106 VCAM-1 Activated endothelial cells, stromal cells 
CD141 
Thrombomoduli
n  
Endothelial cells, keratinocytes, platelets, 
monocytes, neutrophils 
CD146 P1H12, S-endo-1 
Endothelial cells, activated T-Lymphocytes, 
melanoma cells, trophoblast 
Tissue factor  Endothelial cells, monocytes/macrophages 
Table 1. Antigens of endothelial cells, which are also present on non-endothelial cells 
3. Circulating endothelial cells in vasculitis 
Circulating endothelial cells (CEC) are detectable in peripheral blood after they have been 
detached from the damaged endothelial monolayer, probably leaving behind a denuded 
basement membrane. Those cells were first described almost 40 years ago 10 although 
methods of their identification were rather primitive. ANCA-associated small-vessel 
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vasculitis serves as a paradigm of an endothelial disorder. Therefore it is not surprising that 
high numbers of CEC are detected in ANCA vasculitis and correlate with disease activity 11. 
Phenotypic analysis, however, proved more difficult than anticipated. It is quite clear from 
the concept of small vessel vasculitis that CEC cannot be specific to ANCA vasculitis. Dang 
and colleagues reported elevated CEC numbers in aortoarteritis 12 while Nakatani et al. 
demonstrated CECs in patients with Kawasaki disease 13. CEC are also elevated in systemic 
lupus erythematosus 14 and Behcet’s 15. In a broader sense, CEC are also markedly elevated 
in other, non-vasculitic, forms of widespread acute vasculopathy, such as thrombotic 
microangiopathy 16. In addition, CEC can be useful to monitor treatment and to distinguish 
between relapse and infection in difficult cases 17. Patients with relapse of vasculitis had 
markedly elevated numbers of circulating endothelial cells and indeed similar cell numbers 
when compared to patients at their initial vasculitic presentation18. Patients with limited 
disease due to granulomatous ANCA-associated vasculitis had only slightly elevated cell 
numbers, which were similar to those seen in remission. Patients with infection had no 
elevated CEC numbers 18. These findings gave us confidence in the clinical use of CEC in 
vasculitis 17, 19 although prospective data on the clinical use of CEC are lacking.  
 
 CEC EPC 
Cell type Mature endothelium Endothelial 
progenitor cell 
Origin Vessel wall Bone marrow 
Morphology Cells, a-nuclear carcasses or sheets of multiple 
cells 10-100m 
Diameter less than 
20m 
Characteristic 
properties 
VWF 
CD 31 
Thrombomodulin 
CD 146 
UEA-1 
CD 133 
CD 34 
TIE-2 
KDR 
Uptake of acetylated 
LDL 
UEA-1 (unclear) 
Colony-forming 
potential 
None (controversial) Yes 
Laboratory methods Immunomagnetic isolation, FACS FACS, culture assays 
Table 2. Characteristic properties of CEC and EPC 
3.1 CEC and vasculitis: Immunomagnetic isolation and FACS in competition 
The mainstay of immunomagnetic isolation is the use of paramagnetic particles 
(DynabeadsTM), which have been coated with anti-endothelial antibodies as reviewed in 
great detail elsewhere 10. Briefly, whole blood is incubated with antibody-labeled magnetic 
DynabeadsTM. Next, target cells with bound anti-endothelial antibody and DynabeadsTM are 
recovered with a magnet. CEC can then be enumerated after acridine staining. 
Immunomagnetic capturing is mostly performed using the cell surface marker CD 146 20.  
A variety of factors has been considered to influence CEC counts 21. To avoid false positive 
results caused by traumatic venepuncture (resulting in dislodgement of endothelial cells 
from the vessel wall) it is recommended to discard the first tube of blood 20. Adding albumin 
www.intechopen.com
 
Advances in the Etiology, Pathogenesis and Pathology of Vasculitis 
 
182 
or EDTA and Fc-blocking agents is employed to reduce non-specific binding of anti-CD 146-
coupled beads to leukocytes although this remains a concern even in experienced hands 22. 
Moreover, activated T-lymphocytes and other cell subsets may under some circumstances 
also harbor CD 146 and lead to artifacts 23. We therefore developed a secondary stain with 
Ulex Europaeus lectin 1 (UEA-1). 24 Even so and despite the proposal of a consensus for 
definition of CEC the approach remains time consuming and require considerable 
experience. Automated systems have been described but these are costly 25.  
Flow cytometry is an alternative technique to isolate and enumerate CEC 26-31. The technique 
holds considerable promise, as several surface markers can be used concurrently. For 
example, CD 146 expression on activated T cells can be distinguished from CD 146 on 
endothelial cells by co-staining with CD45 or CD3 (or both). CD 133 may help to identify 
EPC because it is not present on CEC or any mature endothelial cells. The addition of 
viability stains, such as propidium iodide or 7-AAD, may also help to identify EPC. Markers 
of endothelial activation can be studied as well. Most groups define CEC using flow 
cytometry as CD146+, CD34+ and CD45- 32. Others have defined CEC as CD31bright, 
CD34+CD45-, CD133- 33 34. However, CD31 bright could also include platelets, resulting in 
falsely elevated numbers of CEC 35.  
Unlike immunomagnetic isolation, FACS does not permit visualization of the cell. 
Furthermore the cell numbers obtained with FACS differ markedly from those obtained 
with immunomagnetic isolation, whereby higher numbers are usually observed with FACS. 
In addition, there is considerable discrepancy in these numbers between different groups 
that employ FACS. It is remarkable that most if not all investigators using immunomagnetic 
isolation enumerate in the range of 10 CEC/ml blood in healthy individuals while those 
using FACS report cell numbers in the thousands per ml with a fairly broad range 10: 
Holmen and colleagues measured a mean of 50 CEC/ml in healthy controls 26, Mancuso et 
al. counted 1,200 CEC/ml of rested cells 36 and Jacques N et al. 6.5 CEC/ml 37. Two groups 
compared CEC counts measured with both methods in the same populations. Goon et al. 
measured 8 CEC/ml in healthy controls comparable to CEC detection by IB (4.5CEC/ml) 32. 
In contrast, Clarke et al. detected lower numbers of CEC by FC compared to IB 38 suggesting 
limited sensitivity for the detection of CECs. Further validation studies are required to 
determine the influence of gating, CEC phenotype, and “lysing”, which could reduce 
recovery of CEC.  
In comparison to immuno-magnetic isolation, FACS holds considerable promise and 
technical advantages. In addition, FACS is less time consuming and easily amenable to 
standardization. Cost is difficult to compare with immunomagnetic isolation, given the 
expenditure for the FACS counter and the fact that the cost of experienced staff is difficult to 
gauge. Very recently alternative approaches have combined the two techniques 39. This 
novel tool has to be validated in other clinical settings and populations. 
3.2 Phenotype and mechanisms of detachment of CEC in vasculitis 
Endothelial cells can be activated by various stimuli, such as pro-inflammatory cytokines, 
growth factors, infectious agents, lipoproteins, or oxidative stress. Loss of integrity of the 
endothelial layer eventually leads to cell detachment of cells 40. Such detachment can be 
caused by defective adhesive properties of the endothelial cells, by action of proteases 
and/or cytokines or, by mechanical injury. Endothelial adhesive molecules of the integrin 
and cadherin family, such as vitronectin and fibronectin and VE cadherin, respectively, 
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promote adhesion of endothelial cells to matrix 40-41. Loss of these survival signals triggers 
detachment and apoptosis of endothelial cells 42. Protective factors have been described as 
well: In sickle cell disease endothelial apoptosis is impaired by VEGF. This has also been 
shown in vitro, where VEGF inhibits apoptosis of unanchored culture cells 43. Release of 
proteases by granulocytes is another well-documented cause of endothelial cell detachment 
44-45 46 47. Finally, mechanical force can detach endothelial cells from the basement membrane 
as shown in patients undergoing percutaneous catheter interventions 48.  
Not much is known regarding the phenotype of CEC. This is caused mainly by the paucity 
of CEC even in active disease and in the difficulty of characterizing these cells further. 
Moreover, it is difficult to say with certainty whether or not phenotypic changes were 
induced by the isolation procedure itself. The viability of CEC remains particularly 
controversial. Our own data suggest that CEC in ANCA-associated small-vessel vasculitis 
are mainly necrotic 11 and we were unable to culture these cells. Others, however, describe 
culture of CEC that were isolated by FACS. In contrast, two-thirds of CEC in normal 
subjects are believed to be apoptotic 49. Lin et al could also demonstrate that vessel-wall 
derived CD146+ CEC can be viable, although they have limited growth capability 50. 
Another group was recently able to grow CEC for about 10 days, but no significant 
proliferative capacity was observed 26.  
3.3 Circulating endothelial cells as potential mediators of disease 
It has been speculated that CEC themselves could be pro-inflammatory 40. In general, 
damaged eukaryotic cells have been shown to release a variety of pro-inflammatory factors, 
to initiate pro-inflammatory pathways in other cell subsets, such as a Toll-like-receptor-
2/NFκB-dependent reaction in monocytes 51. In highly active vasculitis, the healthy 
endothelium must surely encounter a vast array of apoptotic and/or necrotic endothelial 
cells and their debris. Disturbed clearance of apoptotic cells may play a role in systemic 
lupus erythematosus 52. Interestingly, apoptotic and necrotic endothelial cells and their 
fragments are rapidly internalized by healthy endothelium 53. Support for these findings 
came from other studies demonstrating the phagocytic capability of endothelial cells 54. We 
could also show that endothelial cells exposed to apoptotic and necrotic cells exhibit 
enhanced adhesion properties for leukocytes and that isolated CEC from patients with 
vasculitis aggravated these effects further 53. These effects on binding properties could be 
explained in part by release of IL-8 and MCP1, which serve as chemo-attractants. 
Interestingly, apoptotic and necrotic cells induced different patterns of effects in healthy 
endothelium. Enhanced IL-8 and MCP1 levels in serum have been detected in patients with 
active vasculitis and ANCA induce the synthesis of these chemokines in various cell subsets 
55. Endothelial synthesis of these mediators triggered by ANCA 56 and circulating 
endothelial cells 53 may contribute to the pro-inflammatory state associated with vasculitis.  
We have investigated this topic further and became interested in thrombospondin (TSP-1) as 
a possible mediator. This multi-functional glycoprotein is a known endogenous inhibitor of 
angiogenesis 57 and modulates cell adhesion and proliferation 58. We were able to show that 
apoptotic cells induce expression of TSP-1 in endothelial cells 59 and that TSP-1 facilitates 
engulfment of apoptotic cells by phagocytes 59. We speculate that under pathological 
conditions with high numbers of un-cleared dying cells in the circulation endothelial-
derived elevated TSP-1 level may serve as an attraction signal for phagocytes promoting 
enhanced recognition and clearance of apoptotic cells.  
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It is probably fair to say that at present we do not understand the interactions between CEC 
and healthy endothelium and other cell subsets. Further studies, for example in animal 
models, are surely warranted. Figure 1 summarizes proven and proposed interactions of 
circulating endothelial cells with healthy endothelium.  
4. Microparticles in vasculitis: Just smaller than CEC or different, too? 
Microparticles (MP) are sub-micrometric fragments derived from plasma membranes in 
response to a variety of events, such as activation, injury, or apoptosis. Loss of phospholipid 
asymmetry and increased surface expression of phosphatidylserine are crucial events in this 
process 60-61. On their surface these particles express antigens that reflect their cellular origin, 
which permits their enumeration and characterisation by flow cytometry. In addition eMP 
have a functional role as mediators of inflammation or coagulation. In general, 
microparticles have attracted considerable interest in vascular disease although a consensus 
definition of these particles and a uniformly accepted protocol for their enumeration is still 
lacking 62. To make matters even more complicated, endothelial microparticles represent a 
small subgroup of all MP found in plasma63. Specific endothelial microparticles were first 
described in 1990 by Hamilton and colleagues 64. On balance, it is probably fair to say that 
the field of microparticles is fraught with similar technical issues as that of CEC and that 
further standardisation is eagerly awaited.  
We studied endothelial microparticles (EMP) by FACS analysis and found elevated EMP in 
active vasculitis 65. Similar results had previously been obtained in a paediatric cohort of 
vasculitis patients 60 66. Particle counts also correlated with disease activity 65. The difficult 
bit is that CECs and microparticles may not reflect the same disease process. Incidentally, 
the same holds true for soluble endothelial markers, such as soluble von Willebrand factor 
or thrombomodulin: CEC, EMP and soluble markers may represent different mechanisms of 
endothelial activation and damage. For example, soluble markers and EMP may already be 
elevated in endothelial activation whereas presence of CEC probably reflects true damage. 
Interestingly CEC and eMP also follow different kinetics in ANCA-associated vasculitis: 
CEC decline slowly during successful immunosuppressive therapy while activated eMP 
probably represent an early marker that normalises quickly 65. To make matters even more 
complicated, each of these markers may underlie different confounding factors: eMP are 
elevated in patients with renal diseases including those on hemodialysis 67 and could reflect 
vascular damage in these patients whereas CEC are not increased in renal failure 11. 
Nevertheless, ESRD patients with and without a history of cardiovascular disease causing 
possible endothelial damage had similar levels of EMP 68. This illustrates that phenotyping 
of microparticles and characterization of subgroups of microparticles for each different 
disease process will be crucial as each disease process will release different microparticles.  
Finally, EMP may also have pathogenetic importance in vasculitis. Microparticles are now 
regarded as crucial players at the interface of atherosclerosis and inflammation 69. MP are 
generally capable of inducing cytokine release 70 and leukocyte MP induce endothelial IL-6 
and MCP-1 production 71. It has been demonstrated that endothelial microparticles convert 
plasminogen into plasmin 72 and are tissue-factor positive 73 . Burkhart et al. demonstrated 
recently that microparticle tissue factor activity is increased in PR3-ANCA vasculitis 
patients with active disease 74.  
Evidence has also emerged to suggest that endothelial release of microparticles from 
adherent cells is actually protective and that inhibition of microparticle release leads to 
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endothelial detachment 75.  Moreover, pre-treatment of endothelial cells and monocytes with 
platelet derived MP modulates monocyte-endothelial cell interactions by increasing the 
expression of adhesion molecules on both cell types 76. EMP have been shown to decrease 
nitric-oxide-dependent vasodilation and to be both pro-inflammatory and pro-coagulant 61. 
MP have also been found to stimulate angiogenesis and differentiation of progenitor cells 77. 
Finally, elegant studies in flow chambers have demonstrated that MP enhance leukocyte 
rolling 78. Taken together, current data suggest that EMP may not only be a surrogate 
marker of vasculitis but that they may contribute to the pro-inflammatory and pro-
coagulant status of the endothelium. It must be remembered, however, that findings in 
generic microparticles may not be applicable to EMP and vice versa.  
5. CEC and EPC – an ongoing controversy 
The role of endothelial progenitor cells (EPC) 79 in vascular disease and their potential role 
for therapy 80 have been reviewed recently 81. Of note, the field of EPC is particularly 
hampered by lack of standardisation 82 83. Our knowledge about the kinetics of CEC 
detachment and EPC mobilisation as well as their interaction is equally limited. Very 
recently, the margins between endothelial progenitor cells and haematopoietic stem cells 
became somewhat blurred after proof that endothelial cells can be haematopoietic in mice 84.  
We have previously studied numbers of circulating CD34+ progenitor cells and EPCs in 
vasculitis and demonstrated that these cells increased significantly after the institution of 
immunosuppressive therapy and with disease remission 85. Others have previously 
described an increase in EPCs in inflammatory vascular diseases: Avouac and colleagues, 
for instance, described increased EPC numbers in scleroderma 86. In contrast to de Groot and 
co-workers 85, other studies postulate an imbalance between CECs and EPCs in patients 
with vasculitis 26 87. Another study by Zavada and colleagues reports reduced EPC numbers 
as a risk factor for relapse in vasculitis 88. Of note, the pattern of EPC in vasculitis may be 
different in children and one group reports increased numbers in active vasculitis 66. EPCs 
were also measured in other subgroups of vasculitis. In Behcet’s vasculitis EPC were 
decreased 89, in children with Kawasaki disease  EPC were increased 90.  
What make these studies so difficult to compare is, again, the lack of standardisation and the 
use of different assays and surface markers. Of note, the field of EPC is particularly 
hampered by lack of standardisation 82 83. The population of EPC may include a group of 
cells existing in a variety of stages ranging from immature hematopoietic stem cells to 
completely differentiated endothelial cells. Endothelial markers, such as CD-146 and UEA-1 
are also present on EPC. However, the severely damaged morphology of cells obtained by 
CD-146-driven immunomagnetic isolation and our inability to growth these cells in culture 
11 was regarded as indication that these cells are not EPC. Our own experience shows that 
CD 146 positive cells were CD 133 negative 91. Very recently, however, Delorme and co-
workers clearly demonstrated EPC among a population of cells isolated by CD-146-driven 
immunomagnetic isolation 92. Although their findings need corroboration, new protocols of 
immunomagnetic isolation may be needed to exclude EPC. Table 2 summarizes 
characteristic properties of CEC and EPC.  
Therefore, the studies mentioned above provide interesting food for thought but require 
independent confirmation. What stimulates EPCs in reaction to ischemia or other forms of 
insult? There is conclusive evidence that EPC are not stimulated by the non-specific acute 
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phase response 93 but by microvascular injury 94. A variety of specific factors have been 
implicated in this mechanism: First, it is worthwhile to remember that erythropoietin (EPO) 
regulates EPCs 95. Hence EPO treatment must always be corrected for when EPCs are 
measured in renal patients. Statins also influence EPC numbers 96. Other factors that have 
been implicated as regulators of EPCs include vascular endothelial growth factor (VEGF), 
the angiopoetins, and platelet-derived growth factor CC (PDGF-CC). Haeme oxygenase 1 
(HO1) has been implicated as well 97. It is clear that EPCs are capable of homing in to sites of 
vascular damage. Mechanisms include CD18/ICAM-1 and sdf-1/CXCR4. Endothelial 
commitment requires histone deacylase (HDAC) activity and depends on the expression of 
the homoeobox transcription factor HoxA9 98. It is probably fair to say that EPCs will receive 
further scientific attention in vasculitis while a standard as to their definition and 
enumeration is eagerly awaited.  
 
 
Fig. 1. Interactions of apoptotic and necrotic circulating endothelial cells with healthy 
endothelium; from 100, with permission 
6. Conclusion 
Endothelial activation and damage is a crucial event during the pathogenesis of vasculitis. 
Not surprisingly, markers of such damage are detectable in peripheral blood. Several 
markers have been studied. Circulating endothelial cells are an established and reliable 
marker of vascular damage. Cell numbers do correlate with the activity of vascular disease 
and their use in a clinical setting is on the horizon. In comparison, endothelial microparticles 
are smaller and their presence may reflect a different stage of the inflammatory process. For 
both approaches, the lack of standardization remains a matter of particular concern and 
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further multi-centre efforts should be encouraged. Interactions of CEC with the healthy 
endothelium and other cells deserve further attention, as does the phenotype of CEC. 
Endothelial repair is another facet of the inflammatory process although, again, progress is 
hampered by lack of standardization. Taken together, all of these markers may be useful to 
assess vascular inflammation and repair in a clinical setting.  
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